Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0 Clinical Trial to Evaluate Drug Concentrations and Pharmacodynamic Parameters of Niraparib in Tumor Tissue of Patients With Surgically Accessible Recurrent IDH 1/2 Gliomas

NCT05406700 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT05406700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05406700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0 Clinical Trial to Evaluate Drug Concentrations and Pharmacodynamic Parameters of Niraparib in Tumor Tissue of Patients With Surgically Accessible Recurrent IDH 1/2 Gliomas
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 18, 2023
Completion date
October 31, 2026
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, malignant, idh1 mutation, idh2 gene mutation, low-grade glioma, recurrent glioma